Delivering >90% compliance in real-world studies
Book a demo today and see how uMotif’s eCOA/ePRO platform drives unparalleled levels of patient engagement to transform the speed, quality and accuracy of data.
uMotif’s eCOA/ePRO platform is designed for patients first. It powers unrivaled patient engagement and is trusted by leading pharma & biotech organizations across the globe.
uMotif’s next generation eCOA/ePRO platform covers all aspects of clinical, post-marketing and real-world research.
Our deep understanding of how to engage patients to help them overcome the burden of trail participation is proven to achieve >90% eCOA/ePRO compliance and reduce study timelines by up to 30%.
Our patient-first approach has powered all study sizes, from large-scale virtual studies with over 13,000 participants, all the way down to pediatric rare disease studies with just 60 critical families.
Insights from our patient engagement experts
uMotif eCOA/ePRO platform helps to expand understanding of hypoglycaemic events
Find out more about uMotif’s role in the groundbreaking Hypo-METRICS study, which investigated the impact of hypoglycaemia on patients’ lives.Read blog
Case study: 100 for Parkinson’s
uMotif eCOA/ePRO platform powers multi-nation decentralized study, helping people with Parkinson’s Disease better understand symptoms and creating a strong data foundation future research.Read case study
How uMotif’s eCOA / ePRO app supports patient engagement and helps them manage their condition
Hear the story of Cathy, a Parkinson’s patient, and how using the uMotif eCAO/ePRO app not only enabled her to take part in this study but is having a positive impact on the management of her condition.
Over 90% compliance in real-world studies
Reducing study timelines by ⅓
Capturing GCP-compliant data, ready for submission
“We needed an easy-to-use solution, that can be used across multiple countries, to manage a high volume of data capture – uMotif’s platform provides the opportunity to engage our patients”
Professor Pratik Choudhary Project Lead, King’s College London